Literature DB >> 11716800

Vasopeptidase inhibition and endothelial function in hypertension.

L V d'Uscio1, T F Lüscher.   

Abstract

Vasopeptidase inhibitors are a new class of drugs capable of inhibiting both angiotensin-converting enzyme and neutral endopeptidase 24.11. This involves simultaneous inhibition with a single molecule of two key enzymes, ACE and NEP, which are both involved in the regulation of cardiovascular homeostasis in many ways. This includes metabolism of several vasoactive peptides and their clearance from the circulation, therefore contributing to neurohumoral modulation, which might have therapeutic advantages in the prevention of endothelial dysfunction in hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716800     DOI: 10.1007/s11906-001-0101-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  93 in total

1.  Cardiovascular effects of brain natriuretic peptide in essential hypertension.

Authors:  G La Villa; G Bisi; C Lazzeri; C Fronzaroli; L Stefani; G Barletta; R Del Bene; G Messeri; G Strazzulla; F Franchi
Journal:  Hypertension       Date:  1995-05       Impact factor: 10.190

2.  Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.

Authors:  M T Rademaker; C J Charles; E A Espiner; M G Nicholls; A M Richards; T Kosoglou
Journal:  J Cardiovasc Pharmacol       Date:  1998-01       Impact factor: 3.105

3.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

4.  Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma.

Authors:  A J Stingo; A L Clavell; D M Heublein; C M Wei; M R Pittelkow; J C Burnett
Journal:  Am J Physiol       Date:  1992-10

5.  Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop.

Authors:  G F Alberts; K A Peifley; A Johns; J F Kleha; J A Winkles
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

6.  Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase.

Authors:  W C Sessa; J K Harrison; C M Barber; D Zeng; M E Durieux; D D D'Angelo; K R Lynch; M J Peach
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

7.  Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition.

Authors:  P Moreau; H Takase; C F Küng; M M van Rooijen; T Schaffner; T F Lüscher
Journal:  Stroke       Date:  1995-10       Impact factor: 7.914

8.  Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.

Authors:  I Pham; W Gonzalez; A I el Amrani; M C Fournié-Zaluski; M Philippe; I Laboulandine; B P Roques; J B Michel
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

9.  Endothelin receptor subtypes in small arteries. Studies with FR139317 and bosentan.

Authors:  H Takase; P Moreau; T F Lüscher
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

10.  Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor.

Authors:  I Pörsti; A T Bara; R Busse; M Hecker
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.